{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:48:25Z","timestamp":1785422905184,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T00:00:00Z","timestamp":1404950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Cumulative evidence from epidemiological, preclinical and clinical studies suggests estrogens may have psychoprotective effects in schizophrenic patients. Selective Estrogen Receptor Modulators could have therapeutic benefits in schizophrenia for both sexes without being hazardous to gynecological tissues or having feminizing effects. Few studies have been conducted regarding the effects of raloxifene on postmenopausal women suffering from schizophrenia. We conducted this placebo-controlled trial to compare the add-on effect of raloxifene to risperidone versus risperidone with placebo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was an 8-week, parallel-group, placebo-controlled trial undertaken at two universities affiliated psychiatric Hospitals in Iran. Forty-six postmenopausal women with the definite diagnosis of schizophrenia were enrolled in the study. Patients received risperidone (6 mg\/day in 3 divided doses) combined with either placebo (N = 23) or 120 mg\/day of raloxifene (N = 23) for 8 weeks. Patients were assessed by a psychiatrist at baseline and at 2 and 8 weeks after the start of medical therapy. Efficacy was defined as the change from baseline to endpoint in score on Positive and Negative Syndrome Scale (PANSS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>For PANSS scores, the main effect comparing two types of intervention was not significant [F (1, 48) = 1.77, p = 0.18]. For positive subscale scores, there was marginal significant interaction between intervention type and time [F (2, 47) = 2.93, p = 0.06] and there was substantial main effect for time [F (2, 47) = 24.39, p = 0.001] within both groups showing reduction in positive subscale scores across the three time periods. In addition, the main effect comparing two types of intervention was significant [F (1, 48) = 3.78, p = 0.02]. On the other hand, for negative subscale scores, the main effect comparing two types of intervention was not significant [F (1, 48) = 1.43, p = 0.23]. For general subscale scores, the main effect comparing two types of intervention was not significant [F (1, 48) = 0.03, p = 0.86].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>According to our findings, raloxifene as an adjunctive treatment to risperidone was only superior in improvement of positive symptoms and it was not effective in treating negative and general psychopathology symptoms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>The trial was registered at the Iranian registry of clinical trials: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.irct.ir\/searchresult.php?keyword=raloxifen&amp;id=1556&amp;number=42&amp;field=g&amp;prt=3&amp;total=5&amp;m=1\" ext-link-type=\"uri\">IRCT201205131556N42<\/jats:ext-link>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/2008-2231-22-55","type":"journal-article","created":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T17:01:44Z","timestamp":1405011704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Gilda","family":"Kianimehr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Fatehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hashempoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Reza","family":"Khodaei-Ardakani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzin","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Nazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Kashani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Akhondzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,10]]},"reference":[{"issue":"7","key":"217_CR1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2165\/11630660-000000000-00000","volume":"26","author":"J Kulkarni","year":"2012","unstructured":"Kulkarni J, Gavrilidis E, Worsley R, Hayes E: Role of estrogen treatment in the management of schizophrenia. CNS Drugs. 2012, 26 (7): 549-557. 10.2165\/11630660-000000000-00000.","journal-title":"CNS Drugs"},{"issue":"1","key":"217_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1586\/14737175.7.1.45","volume":"7","author":"AM Mortimer","year":"2007","unstructured":"Mortimer AM: Relationship between estrogen and schizophrenia. Expert Rev Neurother. 2007, 7 (1): 45-55. 10.1586\/14737175.7.1.45.","journal-title":"Expert Rev Neurother"},{"issue":"2\u20133","key":"217_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.schres.2012.08.016","volume":"141","author":"MJ Begemann","year":"2012","unstructured":"Begemann MJ, Dekker CF, van Lunenburg M, Sommer IE: Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr Res. 2012, 141 (2\u20133): 179-184.","journal-title":"Schizophr Res"},{"issue":"8","key":"217_CR4","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.psyneuen.2010.01.014","volume":"35","author":"J Kulkarni","year":"2010","unstructured":"Kulkarni J, Gurvich C, Lee SJ, Gilbert H, Gavrilidis E, de Castella A, Berk M, Dodd S, Fitzgerald PB, Davis SR: Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology. 2010, 35 (8): 1142-1147. 10.1016\/j.psyneuen.2010.01.014.","journal-title":"Psychoneuroendocrinology"},{"issue":"6","key":"217_CR5","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0278-5846(03)00161-1","volume":"27","author":"S Akhondzadeh","year":"2003","unstructured":"Akhondzadeh S, Nejatisafa AA, Amini H, Mohammadi MR, Larijani B, Kashani L, Raisi F, Kamalipour A: Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2003, 27 (6): 1007-1012. 10.1016\/S0278-5846(03)00161-1.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"217_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2217\/14750708.2.5.745","volume":"2","author":"S Akhondzadeh","year":"2005","unstructured":"Akhondzadeh S, Mokhberi K, Amini H, Larijani B, Kashani L, Hashemi L, Nejatisafa AA, Shafaei AR: Is there a relationship between estrogen serum level and symptom severity throughout the menstrual cycle of patients with schizophrenia?. Therapy. 2005, 2 (5): 745-751. 10.2217\/14750708.2.5.745.","journal-title":"Therapy"},{"key":"217_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neuroscience.2012.10.024","volume":"239","author":"YC Wu","year":"2013","unstructured":"Wu YC, Hill RA, Gogos A, van den Buuse M: Sex differences and the role of estrogen in animal models of schizophrenia: interaction with BDNF. Neuroscience. 2013, 239: 67-83.","journal-title":"Neuroscience"},{"issue":"4","key":"217_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.yhbeh.2012.01.010","volume":"61","author":"DA Velazquez-Zamora","year":"2012","unstructured":"Velazquez-Zamora DA, Garcia-Segura LM, Gonzalez-Burgos I: Effects of selective estrogen receptor modulators on allocentric working memory performance and on dendritic spines in medial prefrontal cortex pyramidal neurons of ovariectomized rats. Horm Behav. 2012, 61 (4): 512-517. 10.1016\/j.yhbeh.2012.01.010.","journal-title":"Horm Behav"},{"issue":"11","key":"217_CR9","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.4088\/JCP.10m06610","volume":"72","author":"J Usall","year":"2011","unstructured":"Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M, Serrano-Blanco A, Teba F, Ochoa S: Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2011, 72 (11): 1552-1557. 10.4088\/JCP.10m06610.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"217_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.euroneuro.2013.11.012","volume":"24","author":"E Huerta-Ramos","year":"2014","unstructured":"Huerta-Ramos E, Iniesta R, Ochoa S, Cobo J, Miquel E, Roca M, Serrano-Blanco A, Teba F, Ochoa S: Effects of raloxifene on cognition in postmenopausal women with schizophrenia: A double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2014, 24 (2): 223-231. 10.1016\/j.euroneuro.2013.11.012.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"217_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13 (2): 261-276. 10.1093\/schbul\/13.2.261.","journal-title":"Schizophr Bull"},{"issue":"6","key":"217_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/WNF.0000000000000001","volume":"36","author":"M Farokhnia","year":"2013","unstructured":"Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, Moghadam M, Gharibi F, Mirshafiee O, Akhondzadeh S: N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2013, 36 (6): 185-192. 10.1097\/WNF.0000000000000001.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"217_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00213-013-3261-z","volume":"231","author":"M Farokhnia","year":"2014","unstructured":"Farokhnia M, Sabzabadi M, Pourmahmoud H, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Akhondzadeh S: A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Psychopharmacology (Berl). 2014, 231 (3): 533-542. 10.1007\/s00213-013-3261-z.","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"217_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.psychres.2013.12.051","volume":"215","author":"MR Khodaie-Ardakani","year":"2014","unstructured":"Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A, Rezaei F, Salehi B, Yekehtaz H, Ashrafi M, Tabrizi M, Akhondzadeh S: Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. Psychiatry Res. 2014, 215 (3): 540-546. 10.1016\/j.psychres.2013.12.051.","journal-title":"Psychiatry Res"},{"issue":"6","key":"217_CR15","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.euroneuro.2014.02.001","volume":"24","author":"SM Hosseini","year":"2014","unstructured":"Hosseini SM, Farokhnia M, Rezaei F, Gougol A, Yekehtaz H, Iranpour N, Salehi B, Tabrizi M, Tajdini M, Ghaleiha A, Akhondzadeh S: Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial. Eur Neuropsychopharmacol. 2014, 24 (6): 846-855. 10.1016\/j.euroneuro.2014.02.001.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2\u20133","key":"217_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","volume":"76","author":"G Chouinard","year":"2005","unstructured":"Chouinard G, Margolese HC: Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005, 76 (2\u20133): 247-265.","journal-title":"Schizophr Res"},{"key":"217_CR17","volume-title":"Mol Psychiatry","author":"J Kulkarni","year":"2014","unstructured":"Kulkarni J, Gavrilidis E, Wang W, Worsley R, Fitzgerald PB, Gurvich C, Van Rheenen T, Berk M, Burger H: Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry. 2014, doi:10.1038\/mp.2014.33"},{"issue":"2","key":"217_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00737-012-0259-1","volume":"15","author":"D Raveendranathan","year":"2012","unstructured":"Raveendranathan D, Shivakumar V, Jayaram N, Rao NP, Venkatasubramanian G: Beneficial effects of add-on raloxifene in schizophrenia. Arch Womens Ment Health. 2012, 15 (2): 147-148. 10.1007\/s00737-012-0259-1.","journal-title":"Arch Womens Ment Health"},{"key":"217_CR19","volume-title":"Cochrane Database Syst Rev","author":"WL Chua","year":"2005","unstructured":"Chua WL, de Izquierdo SA, Kulkarni J, Mortimer A: Estrogen for schizophrenia. Cochrane Database Syst Rev. 2005, 4: CD004719"},{"issue":"2","key":"217_CR20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.yfrne.2007.08.006","volume":"29","author":"JL Spencer","year":"2008","unstructured":"Spencer JL, Waters EM, Romeo RD, Wood GE, Milner TA, McEwen BS: Uncovering the mechanisms of estrogen effects on hippocampal function. Front Neuroendocrinol. 2008, 29 (2): 219-237. 10.1016\/j.yfrne.2007.08.006.","journal-title":"Front Neuroendocrinol"},{"issue":"4","key":"217_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.yfrne.2008.04.001","volume":"29","author":"E Vegeto","year":"2008","unstructured":"Vegeto E, Benedusi V, Maggi A: Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol. 2008, 29 (4): 507-519. 10.1016\/j.yfrne.2008.04.001.","journal-title":"Front Neuroendocrinol"},{"issue":"5","key":"217_CR22","first-page":"334","volume":"39","author":"J Usall","year":"2011","unstructured":"Usall J, Coromina M, Araya S, Ochoa S: Effect of raloxifene (a Selective Estrogen Receptor Modulator (SERM)) as coadjuvant to antidepressant treatment: a case report. Actas Esp Psiquiatr. 2011, 39 (5): 334-336.","journal-title":"Actas Esp Psiquiatr"},{"issue":"3","key":"217_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/schbul\/sbn084","volume":"35","author":"J Welham","year":"2009","unstructured":"Welham J, Isohanni M, Jones P, McGrath J: The antecedents of schizophrenia: a review of birth cohort studies. Schizophr Bull. 2009, 35 (3): 603-623. 10.1093\/schbul\/sbn084.","journal-title":"Schizophr Bull"},{"issue":"5","key":"217_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3109\/09540261.2010.515205","volume":"22","author":"KM Abel","year":"2010","unstructured":"Abel KM, Drake R, Goldstein JM: Sex differences in schizophrenia. Int Rev Psychiatry. 2010, 22 (5): 417-428. 10.3109\/09540261.2010.515205.","journal-title":"Int Rev Psychiatry"},{"issue":"1\u20132","key":"217_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.psychres.2010.06.003","volume":"185","author":"T Kishi","year":"2011","unstructured":"Kishi T, Okochi T, Tsunoka T, Okumura T, Kitajima T, Kawashima K, Yamanouchi Y, Kinoshita Y, Naitoh H, Inada T, Kunugi H, Kato T, Yoshikawa T, Ujike H, Ozaki N, Iwata N: Serotonin 1A receptor gene, schizophrenia and bipolar disorder: an association study and meta-analysis. Psychiatry Res. 2011, 185 (1\u20132): 20-26.","journal-title":"Psychiatry Res"},{"issue":"1","key":"217_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/1534582305277152","volume":"4","author":"Z Amin","year":"2005","unstructured":"Amin Z, Canli T, Epperson CN: Effect of estrogen-serotonin interactions on mood and cognition. Behav Cogn Neurosci Rev. 2005, 4 (1): 43-58. 10.1177\/1534582305277152.","journal-title":"Behav Cogn Neurosci Rev"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2008-2231-22-55.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2008-2231-22-55\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/2008-2231-22-55.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T04:56:13Z","timestamp":1630558573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/2008-2231-22-55"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,10]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["217"],"URL":"https:\/\/doi.org\/10.1186\/2008-2231-22-55","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,10]]},"assertion":[{"value":"17 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"55"}}